Peptilogics
Pittsburg, US · Founded 2013 · Delaware corporation · 22 employees on LinkedIn · 12 known investors
Peptilogics is a clinical-stage surgical therapeutics company developing zaloganan (PLG0206), a novel anti-biofilm drug to treat and prevent medical device-related infections such as prosthetic joint infections. Its lead candidate is in a pivotal Phase 2/3 trial and holds FDA Orphan Disease, Fast Track, and QIDP designations.
Also known as Peptilogics, Inc.
Founders & leadership
Peptilogics was founded in 2013 by Jonathan Steckbeck.
Board
Investors · 12
Funding
SEC filings, press & company announcements$118.9M disclosed across 5 of 6 rounds · 2016–2025
▶$35.8MraisedDec 2020 · 19 investors · BiotechnologyRule 506(b)
- Jonathan SteckbeckExecutive Officer, Director
- Dietrich StephanDirector
- Hannes HolsteDirector
- Jason CammDirector
- Catherine MottDirector
- Offering amount
- $35.8M
- Amount sold
- $35.8M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4MraisedAug 2017 · 1 investors · BiotechnologyRule 506(b)
- Jonathan SteckbeckExecutive Officer, Director
- Stefan RoeverDirector
- Sanjay KakkarExecutive Officer, Director
- Catherine MottDirector
- Dietrich StephanDirector
- Offering amount
- $4M
- Amount sold
- $4M
- First sale
- Aug 2017
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$754KraisedMay 2017 · 7 investors · BiotechnologyRule 506(b)
- Stefan RoeverDirector
- Catherine MottDirector
- Jonathan SteckbeckExecutive Officer, Director
- Dietrich StephanDirector
- Offering amount
- $1.5M
- Amount sold
- $754K
- First sale
- May 2017
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$416.8KraisedJan 2016 · 2 investors · BiotechnologyRule 506(b)
- Stephan DietrichDirector
- Jonathan SteckbeckExecutive Officer, Director
- Offering amount
- $1.6M
- Amount sold
- $416.8K
- First sale
- Jan 2016
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026Peptilogics is a surgical therapeutics company developing a novel anti-biofilm drug intended to cure and prevent medical device-related infections, a condition the company describes as affecting millions of people worldwide and as often life-threatening.
The company's clinical-stage pipeline is led by zaloganan (PLG0206), an anti-biofilm therapeutic. Zaloganan is enrolling the pivotal Phase 2/3 RETAIN trial for the treatment of prosthetic joint infections (PJI), an indication for which the company states there are no approved therapies. Zaloganan holds Orphan Disease Designation from the FDA as well as Fast Track and Qualified Infectious Disease Product (QIDP) status.
Alongside its clinical program, the company maintains resources for healthcare professionals and patients, including materials on living with PJI, clinical trial information, and an expanded access policy.
Traction
Zaloganan (PLG0206) is in clinical development and is currently enrolling the pivotal Phase 2/3 RETAIN trial in prosthetic joint infections; the candidate carries FDA Orphan Disease Designation, Fast Track, and QIDP status.
Latest developments
The pivotal Phase 2/3 RETAIN trial of zaloganan for prosthetic joint infection is open for enrollment.
▸Full profile — market position, technology, go-to-market
Market position
Peptilogics positions zaloganan in prosthetic joint infection, an indication for which the company states no approved therapies exist.
Technology
Zaloganan (PLG0206) is described as a novel anti-biofilm therapeutic aimed at curing and preventing infections associated with implanted medical devices.
Go-to-market
Patients with medical device-related infections, with an initial focus on prosthetic (periprosthetic) joint infection, reached through surgeons and other healthcare professionals involved in device-related infection care.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Competitors · 4
by search overlap
Companies competing with Peptilogics for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline · 1
launches, deals, and filingsThe company states that its lead candidate zaloganan (PLG0206) has Orphan Disease Designation from the FDA, along with Fast Track and Qualified Infectious Disease Product (QIDP) status.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
Legal entities · 1
corporate structureIn the news
▸Research sources · 1
primary sources listed
- Peptilogicspeptilogics.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Peptilogics do?
- Peptilogics is a surgical therapeutics company developing an anti-biofilm drug for medical device-related infections.
- Who founded Peptilogics?
- Peptilogics was founded by Jonathan Steckbeck in 2013.
- Who are Peptilogics's investors?
- Peptilogics's investors include AAF Management Ltd., Alpha Wave Global, AMR Action Fund, Mountain State Capital, Narya Capital, Riverfront Ventures, LLC, Tachyon Ventures, Beyond Ventures and 4 more.
- How much funding has Peptilogics raised?
- Peptilogics has disclosed $118.9M raised across 5 of its 6 known rounds.
- Where is Peptilogics headquartered?
- Peptilogics is headquartered in Pittsburg, US.